Retatrutide offers a novel approach to treating Metabolic dysfunction-associated steatotic liver disease and its severe form, MASH. Acting on multiple metabolic pathways it targets GIP, GLP-1, and glucagon receptors with varying potency. A phase 2 trial showed a 24.2% weight reduction and significant liver fat decrease in patients, with no major safety concerns. Given the lack of approved treatments for MASLD and MASH the drug retatrutide could represent a breakthrough, addressing the pressing unmet need for effective therapies in liver health and metabolic dysfunction.
Sanyal, A.J., Kaplan, L.M., Frias, J.P., Brouwers, B., Wu, Q., Thomas, M.K., Harris, C., Schloot, N.C., Du, Y., Mather, K.J., Haupt, A., and Hartman, M.L., 2024. Retatrutide effects on liver fat and metabolic outcomes in patients with MASLD. Nature Medicine.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Retatrutide by Dragon Pharma, consult with your doctor or healthcare professional.
Sanyal, A.J., Kaplan, L.M., Frias, J.P., Brouwers, B., Wu, Q., Thomas, M.K., Harris, C., Schloot, N.C., Du, Y., Mather, K.J., Haupt, A., and Hartman, M.L., 2024. Retatrutide effects on liver fat and metabolic outcomes in patients with MASLD. Nature Medicine.
Sanyal, A.J., Kaplan, L.M., Frias, J.P., Brouwers, B., Wu, Q., Thomas, M.K., Harris, C., Schloot, N.C., Du, Y., Mather, K.J., Haupt, A., and Hartman, M.L., 2024. Retatrutide effects on liver fat and metabolic outcomes in patients with MASLD. Nature Medicine.
Sanyal, A.J., Kaplan, L.M., Frias, J.P., Brouwers, B., Wu, Q., Thomas, M.K., Harris, C., Schloot, N.C., Du, Y., Mather, K.J., Haupt, A., and Hartman, M.L., 2024. Retatrutide effects on liver fat and metabolic outcomes in patients with MASLD. Nature Medicine.
Home
